FindTrial
Sign In

Placebo plus standard therapy

BIOLOGICAL5 trials

Sponsors

Human Genome Sciences Inc., a GSK Company, GlaxoSmithKline, RemeGen Co., Ltd.

Conditions

Lupus NephritisSystemic Lupus Erythematosus

Phase 2

Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)
CompletedNCT02885610
RemeGen Co., Ltd.Systemic Lupus Erythematosus
Start: 2015-12-31End: 2019-07-09Updated: 2020-03-04

Phase 3

Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis
CompletedNCT01639339
Human Genome Sciences Inc., a GSK CompanyLupus Nephritis
Start: 2012-07-12End: 2020-03-12Updated: 2021-03-19
Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)
CompletedNCT04082416
RemeGen Co., Ltd.Systemic Lupus Erythematosus
Start: 2019-10-16End: 2022-06-30Updated: 2023-05-11

Phase 4

Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)
CompletedNCT01632241
Human Genome Sciences Inc., a GSK CompanySystemic Lupus Erythematosus
Start: 2013-02-19End: 2019-01-28Updated: 2021-09-08
Belimumab Assessment of Safety in SLE
CompletedNCT01705977
GlaxoSmithKlineSystemic Lupus Erythematosus
Start: 2012-11-27End: 2022-08-10Updated: 2024-07-15

Related Papers

Belimumab outperforms placebo for attainment of modified DORIS remission and LLDAS without the glucocorticoid component: a post hoc analysis of five phase III SLE trials.
2026-07-03
PO:15:217 | Improved efficacy and safety outcomes in patients with systemic lupus erythematosus treated with belimumab vs. immunosuppressants, in addition to antimalarials and glucocorticoids: a <i>post-hoc</i> summary of five phase 3 trials
Reumatismo2025-11-26
A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus.
2025-10-013 citations
#1672 Cost-effectiveness analysis of voclosporin vs mycophenolate or belimumab in the treatment of patients with lupus nephritis from the Spanish National Healthcare System perspective
Nephrology Dialysis Transplantation2025-10-01
Phase III/IV, Randomized, Fifty‐Two–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus
UNC Libraries2025-06-04
COMPLETE RENAL RESPONSES AND SAFETY FOR BELIMUMAB VERSUS PLACEBO IN A POST HOC MYCOPHENOLATE MOFETIL SUBGROUP WITH ACTIVE PROLIFERATIVE LUPUS NEPHRITIS
The Journal of Rheumatology2025-05-201 citations
The effect of belimumab on mucocutaneous and vasculitis manifestations in patients with systemic lupus erythematosus: A large pooled post hoc analysis
Lupus2025-05-052 citations
Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus.
2024-09-017 citations
Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials.
2024-08-2615 citations
SF-36v2 and FACIT-Fatigue quality of life improvements with organ-specific SELENA-SLEDAI response and belimumab treatment in patients with systemic lupus erythematosus
Lupus Science & Medicine2024-05-012 citations
Usefulness of Belimumab in Adult Patients With Systemic Lupus Erythematosus Evaluated Using Single Indexes: A Meta-Analysis and Systematic Review
Current Therapeutic Research2024-01-013 citations
Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial
Annals of the Rheumatic Diseases2023-12-21107 citations
Effect of belimumab on kidney-related outcomes in patients with lupus nephritis: post hoc subgroup analyses of the phase 3 BLISS-LN trial
Nephrology Dialysis Transplantation2023-07-1818 citations
LSO-068 Association between organ-specific safety of estrogens in lupus erythematosus national assessment-systemic lupus erythematosus (SLE) disease activity index (SELENA-SLEDAI) response to belimumab and SF-36v2 and FACIT-fatigue scores in patients with SLE
2023-07-01
LSO-028 Predictors of de novo renal flares in systemic lupus erythematosus – time to revisit belimumab dose for extra-renal disease? Results from five phase III clinical trials of belimumab
2023-07-01
1104 Effects of Belimumab (BEL) on Renal Outcomes in Patients (pts) With Relapsed and Newly Diagnosed Active Lupus Nephritis (LN)
Innate Immunity2022-12-01
Safety and Efficacy of Belimumab in Patients with Lupus Nephritis
Clinical Journal of the American Society of Nephrology2022-10-2762 citations
PO.5.105 The effect of belimumab on extra-renal outcomes: results from the phase 3, randomised, placebo-controlled, 104-week bliss-ln study in patients with active lupus nephritis
2022-09-27
PO.5.102 Pharmacokinetic modelling of belimumab in patients with lupus nephritis: intravenous and subcutaneous loading dose regimen justification
2022-09-27
PO.5.101 The effect of belimumab on renal outcomes in a pre-specified subgroup analysis of a phase 3 randomised trial in a european population with lupus nephritis
2022-09-27

16 more papers not shown